Signal active
Organization
Contact Information
Overview
QV Bioelectronics is striving to deliver longer, better quality lives to brain tumour patients through their first of its kind electric field therapy implant, GRACE.
GRACE has been designed alongside some of the leading neurosurgeons in the UK, with the aim of extending patient life expectancy without impacting patient quality of life. For patients with the most common primary brain tumour, glioblastoma, there has been a severe lack of new, effective treatments for decades, with only a handful of approved options. Because of this, glioblastoma has some of the worst outcomes of any cancer, with a 5-year survival rate of <5. Co-founder and academic neurosurgeon Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for patients but also by major design flaws in newer electric field therapy approaches. Working together with Dr Chris Bullock, a biomedical engineer who had been carrying out research at Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life.
QV Bioelectronics was founded to their solution GRACE, to patients. Since then, their ground-breaking materials science research has received nearly $1M in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK, as well as over $1M in equity funding from international life science seed investors SOSV, and renowned life-science investors in Consilience & Catapult Ventures. QV now have an expert, multidisciplinary team with decades of experience working bringing GRACE to the clinic from their research hub in Alderley Park, Cheshire.
About
Biotechnology, Life Science, Health Care, Medical, Electronics, Medical Device, Advanced Materials, Neuroscience, Nanotechnology
2018
11-50
Headquarters locations
Manchester, Manchester, United Kingdom, Europe
Social
Profile Resume
QV Bioelectronics headquartered in Europe, operates in the Biotechnology, Life Science, Health Care, Medical, Electronics, Medical Device, Advanced Materials, Neuroscience, Nanotechnology sector. The company focuses on Biotechnology and has secured $2.0B in funding across 396 round(s). With a team of 11-50 employees, QV Bioelectronics is actively contributing to advancements in Biotechnology. Their latest funding round, Grant - QV Bioelectronics, raised $1.1M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
11
1
0
$5.1M
Details
6
QV Bioelectronics has raised a total of $5.1M in funding over 6 rounds.
Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
---|---|---|---|---|
2020 | Seed | |||
2021 | Seed | 1.0M | ||
2022 | Seed | |||
2023 | Seed | 2.4M |
Investors
QV Bioelectronics is funded by 36 investors.
Investor Name | Lead Investor | Funding Round | Partners |
---|---|---|---|
QV Bioelectronics | - | FUNDING ROUND - QV Bioelectronics | 2.4M |
Empirical Ventures | - | FUNDING ROUND - Empirical Ventures | 2.4M |
QV Bioelectronics | - | FUNDING ROUND - QV Bioelectronics | 1.1M |
Innovate UK | - | FUNDING ROUND - Innovate UK | 1.1M |
Recent Activity
Funding Round
Mar 31, 2023
QV Bioelectronics raised $1061669 on 2023-03-31 in Grant
Funding Round
Jan 10, 2023
QV Bioelectronics raised $2430600 on 2023-01-10 in Seed Round
Funding Round
May 16, 2022
QV Bioelectronics raised an undisclosed amount on 2022-05-16 in Seed Round
News
Mar 04, 2022
Google Patent - Biphasic injectable electrode
News
Mar 04, 2022
Google Patent - Cranial prosthetic
Funding Round
Jun 30, 2021
QV Bioelectronics raised $1016380 on 2021-06-30 in Seed Round